This review concluded that topical application of antifibrinolytics can reduce postoperative bleeding and transfusion requirements in patients who undergo on-pump cardiac surgery, but further preclinical and clinical trials were needed. The conclusions reflected the results of the review and despite some concerns about the synthesis are probably reliable.
Included studies assessed aprotinin or tranexamic acid. All studies used placebo or no treatment control groups (some also compared active treatments) and assessed only primary operations. Most patients were undergoing coronary artery bypass grafts. Patients' mean ages ranged from 49.5 to 65.5 years. The percentage of women ranged from 12.5% to 50%. Anticoagulant medication was discontinued between zero and 14 days before surgery. Antifibrinolytics were administered by pouring into the pericardial cavity and/or over mediastinal tissues at the end of surgery, but before closure of the median sternotomy. They were suctioned out through the chest tubes. Two reviewers independently assessed the studies for inclusion in the review; disagreements were resolved by a third reviewer.
Assessment of study quality
The studies were assessed for validity using the criteria of Schulz et al to appraise randomisation, double-blinding, allocation concealment and completeness of follow up. Two independent reviewers performed the assessment; disagreements were resolved by a third reviewer. Authors were contacted for further information where necessary.
Data extraction
Data were extracted to permit the calculation of mean differences with 95% confidence intervals (CI) for continuous outcomes or relative risks with 95% CIs for dichotomous outcomes. Authors were contacted for additional information where necessary. Blood transfusions reported in mL were converted to units. The authors did not state how many reviewers performed the data extraction.
Methods of synthesis
Random-effects meta-analyses were used to calculate pooled relative risks with 95% CI for dichotomous outcomes and weighted mean differences with 95% CIs for continuous outcomes. It appeared that control groups may have been double-counted where multiple comparisons from a single trial were included in an analysis. Statistical heterogeneity was assessed using the Q and I 2 statistics. A priori subgroup analyses were planned to assess the impact of surgery type, There was a statistically significant benefit associated with treatment for 24-hour postoperative chest-tube blood loss (weighted mean difference -222, 95% CI: -318 to -126; eight RCTs, nine comparisons) and number of red blood cell units transfused (weighted mean difference -1.04, 955 CI: -1.54 to -0.53; five RCTs, seven comparisons). Sensitivity analyses excluding studies that did not meet all quality criteria did not significantly change the results. There was no significant difference between the groups in the incidence of red blood cell transfusion (four RCTs, five comparisons). Statistically significant heterogeneity was found for all of these analyses (I 2 ranged from 55% to 93%).
Subgroup analyses showed significant benefits of aprotinin (five trials) and tranexamic acid (four trials) over placebo for both 24-hour postoperative chest-tube loss and number of red blood cell units transfused, but not for incidence of red blood cell transfusion. Two trials (n=122) assessed both interventions; analysis of these between-drug comparisons showed no statistically significant difference between them for any outcome. One trial (n=97) compared topical with intravenous aprotinin and found no significant difference between the groups for any outcome.
There was no evidence of publication bias in the primary analyses.
Authors' conclusions
The review suggested that topical application of antifibrinolytics can reduce postoperative bleeding and transfusion requirements in patients undergoing on-pump cardiac surgery. However, more trials with large sample sizes, using patient related outcomes and further assessments of the systemic absorption of the medications were needed.
CRD commentary
The review question and the inclusion criteria were clear. The authors searched a number of relevant databases and other sources without language restrictions The lack of restrictions on language or publication status reduced the chance of relevant studies being omitted and of publication or language biases being present. Publication bias was assessed and no evidence was found, although this assessment may not have been reliable due to the small number of included studies. The authors reported using methods designed to reduce reviewer bias and error in the selection of studies and the assessment of validity, but not in the extraction of data. The validity assessment used appropriate criteria, was properly reported and was used to inform the synthesis. The decision to use meta-analysis was probably appropriate, although high levels of statistical heterogeneity were found, which in some cases were not explained by further analysis. The use of double-counting of placebo groups in a small number of instances may have led to an over-estimation of the treatment effect, but this was unlikely to have significantly altered the overall results. In spite of some concerns about the synthesis, the authors' conclusions were an appropriately cautious reflection of this review of a relatively small number of patients. These conclusions are probably reliable.
Implications of the review for practice and research
Practice: The authors did not state any implications for practice.
Research: The authors stated that high quality RCTs with a sample size of at least 60 patients were needed to assess the topical application of tranexamic acid for reduction of postoperative bleeding and transfusion requirements in patients who underwent on-pump cardiac surgery. However, further clinical trials on topical aprotinin for this indication were not recommended until there was further pre-clinical data on the systemic absorption of this medication.
